ERS International Congress 2021: highlights from the Respiratory Infections Assembly

Abstract

The European Respiratory Society Annual Congress 2021 took place virtually for the second year running due to the coronavirus pandemic. The congress programme featured more than 400 sessions and 3000 abstract presentations, covering the entire respiratory science and medicine field. In this article, Early Career Members of the Respiratory Infections Assembly summarise a selection of sessions across a broad range of topics, including presentations on bronchiectasis, non-tuberculosis mycobacteria, tuberculosis, cystic fibrosis and COVID-19.

ERS International Congress 2023: highlights from the Respiratory Infections Assembly

“…Even in the era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, P. aeruginosa infection remains one of the main challenges in people with cystic fibrosis [ 3 , 74 ]. In light of this issue, Urania Rappo (Cambridge, MA, USA) presented a phase 1b/2a trial to evaluate phage therapy with BX004-A for chronic P. aeruginosa pulmonary infection in stable cystic fibrosis patients.…”

“…The congress welcomed over 20 000 attendees on a hybrid platform, bringing together exciting updates in respiratory science and medicine from all over the globe. Following each congress, early career members of the Respiratory Infections Assembly (Assembly 10) produce a highlights article, summarising interesting sessions from this assembly [ 1 – 3 ]. The current article features sessions across a broad range of topics, including presentations on pneumonia, coronavirus disease 2019 (COVID-19), bronchiectasis, nontuberculous mycobacteria (NTM), tuberculosis (TB) and cystic fibrosis.…”

In Vitro Activity of Bedaquiline Against Mycobacterium Fortuitum Complex

“…Это связано как с реальной ситуацией, так и с существенным улучшением диагностики данной патологии [3, 14,24,29].…”